![]() |
![]() |
| Asian Spine J > Volume 19(6); 2025 > Article |
|
No significant differences in operative time, pain, disability, or reherniation between obese and nonobese patients.
Obese patients showed slightly worse Oswestry Disability Index at 6 months, but not at 12 months.
Higher obesity severity (body mass index ≥35 kg/m2) may affect recovery outcomes.
Endoscopic spine surgery is safe and effective in obese patients.
Author Contributions
Every author contributed to this study. Jose Luis Bas, Jorge Campos, and Gonzalo Mariscal wrote the manuscript’s first draft. Hashem Altabbaa and Gonzalo Mariscal conducted the data analysis. Paloma Bas and Teresa Bas made the necessary changes and corrections. The final manuscript was read and approved by all authors.
| Study | Clearly stated aim | Consecutive patients | Prospective collection data | Endpoints | Assessment endpoint | Follow-up period | Loss less than 5% | Study size | Adequate control group | Contemporary group | Baseline control | Statistical analyses | MINORS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bae et al. [21] (2016) | 2 | 2 | 0 | 2 | 1 | 2 | 0 | 0 | 2 | 2 | 2 | 2 | 17 |
| Bergquist et al. [18] (2023) | 2 | 2 | 0 | 2 | 1 | 2 | 2 | 0 | 2 | 2 | 1 | 2 | 18 |
| Leyendecker et al. [22] (2024) | 2 | 2 | 0 | 2 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 2 | 19 |
| Olson et al. [16] (2024) | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 2 | 21 |
| Park et al. [19] (2022) | 2 | 0 | 0 | 2 | 1 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 17 |
| Qu et al. [20] (2023) | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 0 | 2 | 2 | 2 | 2 | 20 |
| Yu et al. [17] (2021) | 2 | 2 | 0 | 2 | 1 | 1 | 0 | 1 | 2 | 2 | 2 | 2 | 17 |
| Study | Region | Total no. of patients | Sex: M (F) | Age (yr) | BMI (kg/m2) | ASA score | Charlson comorbidity index | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
||||||||
| Non-obese | Obese | Non-obese | Obese | Non-obese | Obese | Non-obese | Obese | Non-obese | Obese | |||
| Bae et al. [21] (2016) | Korea | 48 | 12 (15) | 14 (7) | 38.1a) | 37.8a) | 20.8a) | 32.9a) | NA | NA | ||
|
|
||||||||||||
| Bergquist et al. [18] (2023) | USA | 174 | 65 (35) | 44 (30) | 65.2±1.3 | 61.5 ±1.6 | NA | NA | NA | |||
|
|
||||||||||||
| Leyendecker et al. [22] (2024) | Germany | 118 | 39 (26) | 30 (23) | 59.1±17.1 | 55.5±14.7 | 25.9±2.3 | 37.1±5.7 | NA | NA | ||
|
|
||||||||||||
| Olson et al. [16] (2024) | USA | 49 | 13 (13) | 17 (6) | 56.9±19.2 | 60.0±16.4 | 22.6±1.3 | 27.6±4.6 | 1.8±0.7 | 2.3±0.6 | 1.8±1.9 | 2.2±1.9 |
|
|
||||||||||||
| Park et al. [19] (2022) | South Korea | 115 | 41 (45) | 14 (15) | 46.6±15.5 | 44.1±16.2 | 24.3±2.7 | 33.0±3.3 | NA | 0.29±0.68 | 0.59±1.48 | |
|
|
||||||||||||
| Qu et al. [20] (2023) | China | 47 | 15 (13) | 12 (7) | 15.7±2.4 | 16.5±2.6 | 20.2±1.5 | 37.2±3.1 | NA | NA | ||
|
|
||||||||||||
| Yu et al. [17] (2021) | China | 108 | 66 (14) | 24 (4) | 18.6±2.61 | 18.07±2.21 | NA | NA | NA | |||
| Variable | Certainty assessment | No. of patients | Effect | Certainty | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|||||||||||
| No. of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Obese | Non-obese | Relative (95% CI) | Absolute (95% CI) | |||
| Operative time (min) | 3 | Non-randomized studies | Not serious | Seriousa) | Not serious | Very seriousb) | None | 146 | 193 | - | MD, 9.86 higher (4.93 lower to 24.65 higher) | ⊕○○○ Very lowa),b) | Important |
|
|
|||||||||||||
| VAS (back) at 3 mo | 5 | Non-randomized studies | Not serious | Not serious | Not serious | Not serious | None | 152 | 185 | - | MD, 0.26 higher (0.11 lower to 0.63 higher) | ⊕⊕○○ Low | Important |
|
|
|||||||||||||
| VAS (back) at 6 mo | 3 | Non-randomized studies | Not serious | Not serious | Not serious | Not serious | None | 71 | 140 | - | MD, 0.26 higher (0.05 lower to 0.56 higher) | ⊕⊕○○ Low | Important |
|
|
|||||||||||||
| VAS (back) at 12 mo | 3 | Non-randomized studies | Not serious | Not serious | Not serious | Seriousb) | None | 71 | 140 | - | MD, 0.54 lower (1.7 lower to 0.62 higher) | ⊕○○○ Very lowb) | Important |
|
|
|||||||||||||
| VAS (leg) at 3 mo | 5 | Non-randomized studies | Not serious | Not serious | Not serious | Not serious | None | 152 | 285 | - | MD, 0.17 higher (0.06 lower to 0.41 higher) | ⊕⊕○○ Low | Important |
|
|
|||||||||||||
| VAS (leg) at 6 mo | 3 | Non-randomized studies | Not serious | Not serious | Not serious | Not serious | None | 71 | 140 | - | MD, 0.23 higher (0.13 lower to 0.59 higher) | ⊕⊕○○ Low | Important |
|
|
|||||||||||||
| VAS (leg) at 12 mo | 3 | Non-randomized studies | Not serious | Not serious | Not serious | Seriousb) | None | 71 | 140 | - | MD, 0.18 higher (0.1 lower to 0.45 higher) | ⊕○○○ Very lowb) | Important |
|
|
|||||||||||||
| Reherniation | 6 | Non-randomized studies | Not serious | Not serious | Not serious | Very seriousb) | None | 19/194 (9.8%) | 28/347 (8.1%) | OR, 1.35 (0.73 to 2.49) | 25 more per 1,000 (from 20 fewer to 99 more) | ⊕○○○ Very lowb) | Important |
|
|
|||||||||||||
| ODI at 3 mo | 5 | Non-randomized studies | Not serious | Not serious | Not serious | Seriousa) | None | 152 | 285 | - | MD, 1.02 higher (0.14 lower to 2.18 higher) | ⊕○○○ Very lowa) | Important |
|
|
|||||||||||||
| ODI at 6 mo | 3 | Non-randomized studies | Not serious | Not serious | Not serious | Seriousb) | None | 71 | 140 | - | MD, 1.4 higher (0.14 higher to 2.67 higher) | ⊕○○○ Very lowb) | Critical |
|
|
|||||||||||||
| ODI at 12 mo | 3 | Non-randomized studies | Not serious | Not serious | Not serious | Not serious | None | 71 | 140 | - | MD, 0.1 higher (1.14 lower to 1.33 higher) | ⊕⊕○○ Low | Important |

![]() |
![]() |